Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19435575 | 0.79 | KDM4E (0.48) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL617064 | 0.78 | SMN1; SMN2 (0.47) | KDM4ERAB9ANPC1MAPTGAA | |
| SCHEMBL8040045 | 0.77 | NQO2 (0.47) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL11582451 | 0.76 | CA2 (0.54) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL8326622 | 0.76 | KDM4E (0.45) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL8688516 | 0.75 | SMN1; SMN2 (0.44) | KDM4ERAB9ANPC1MAPTGAA | |
| SCHEMBL15001036 | 0.74 | RAB9A (0.57) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL2404277 | 0.74 | MEN1 (0.51) | KDM4ERAB9ANPC1MAPTGAA | |
| SCHEMBL11690597 | 0.72 | CYP3A4 (0.46) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL15880311 | 0.72 | SMN1; SMN2 (0.48) | KDM4ERAB9ANPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041207-A1 | Compound | STERIX LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110009448-A1 | Compound | STERIX LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7786152-B2 | Compound | STERIX LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | STERIX LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-7309715-B2 | Compound | STERIX LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1556040-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | Sterix Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20040143124-A1 | Compound | STERIX LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004037251-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 | STERIX LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114042-A1 | Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer | HSD11B1, HSD3B1, HSD11B2 | KDM4E 2033/4885RAB9A 4048/4885NPC1 2863/4885 |
| US-20110009448-A1 | Compound | NR4A1, GPR6, PRMT6 | KDM4E 565/4885RAB9A 3099/4885NPC1 2357/4885 |
| US-20120041207-A1 | Compound | NR4A1, GPR6, PRMT6 | KDM4E 565/4885RAB9A 3099/4885NPC1 2357/4885 |
| US-20040143124-A1 | Compound | NR4A1, CBR1, NR2C2 | KDM4E 893/4885RAB9A 1545/4885NPC1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.